In a matter involving an antitrust counterclaim, a generic pharmaceutical manufacturer alleged that a blockbuster brand manufacturer attempted to monopolize the market and delay entry of the generic product. A CRA expert was retained to analyze market definition, competitive effects, and lost profits damages estimates. The matter settled favorably for our client shortly before trial.
How Views On US Healthcare Price Transparency Are Changing
Previously in a series of policy letters, Federal Trade Commission staff expressed concerns that transparency could lead to coordinated behavior and higher...